Trial Profile
Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Sep 2016
Price :
$35
*
At a glance
- Drugs Raloxifene (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 20 Jul 2016 According to the results published in the JAMA psychiatry ,Primary endpoint (PANSS score at trial completion (12 weeks)) has not been met.
- 20 Jul 2016 Results published in the JAMA Psychiatry
- 29 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.